Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMN-301
- Development stage
- Phase 1
- Lead developer
- Lumen Bioscience
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral, Intranasal, Inhalation
01
Overview
**LMN-301** is an investigational, spirulina-produced cocktail of SARS-CoV-2-neutralizing antibody-like proteins developed by Lumen Bioscience. The product is designed to bind the SARS-CoV-2 spike glycoprotein and block viral entry into ACE2-expressing cells. It was initially developed as an orally delivered intraluminal therapy for gastrointestinal manifestations of COVID-19 and was subsequently reformulated for intranasal administration for respiratory-tract prophylaxis or treatment. A completed Phase 1 study evaluated intranasal LMN-301 in healthy volunteers. ([lumen.bio](https://www.lumen.bio/news/2021/10/05/lumen-bioscience-awarded-federal-funding-to-advance-covid-19-antibody-cocktail-through-phase-2-clinical-evaluation))
- Other names
- LMN 301LMN301LMN-301
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on LMN-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMN-301.